Protalix BioTherapeutics, Inc. (PLX) insider trading

By person

14 insiders · 12 transactions

13.4×

Dror Bashan holds 13.4 times base salary in stock. $5.40M of shares against $401.84K in salary for 2025.

Salary from the company's own proxy. The shares are what Dror Bashan last reported holding, valued at $1.81, the price Common Stock was last bought or sold at on the open market here, on 19 Dec 2025.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Dexcel Pharma Technologies Ltd. entity

10% owner

—

$2.09M (2)

−$2.09M

3,637,314

4.51%

$6.58M

−20.2%

Camber Capital Management LLC entity

10% owner

—

$792.00K (1)

−$792.00K

10,775,000

13.37%

$19.50M

−18.8%

Aharon Schwartz

Director

$516.96K (3)

—

+$516.96K

310,500

0.3854%

$562.01K

—

Dror Bashan

President and CEO

$293.84K (4)

—

+$293.84K

2,980,861

3.70%

$5.40M

+565.5%

Moshe Manor

President & CEO

$40.50K (1)

—

+$40.50K

50,000

0.0621%

$90.50K

—

Amos Bar-Shalev

Director

—

$314.16 (1)

−$314.16

7,500

0.0093%

$13.58K

+4,364%

Eyal Rubin

Sr. VP and CFO

—

915,156

1.14%

$1.66M

+271.8%

Yaron Naos

Sr. VP & COO

—

225,817

0.2803%

$408.73K

+1,576%

Yael Hayon

VP, Research & Development

—

35,115

0.0436%

$63.56K

—

Eliot Forster

Director

—

7,500

0.0093%

$13.58K

—

Gwen A Melincoff

Director

—

7,500

0.0093%

$13.58K

—

Pol F Boudes

Director

—

7,500

0.0093%

$13.58K

—

Christian Elze

Director

—

7,500

0.0093%

$13.58K

—

Zvi Shmuel Ben

Director

—

7,500

0.0093%

$13.58K

—

Protalix BioTherapeutics, Inc.

What the insiders did Net selling

By person